MicroRNA and metabolomics signatures for adrenomyeloneuropathy disease severity
暂无分享,去创建一个
A. Moser | A. Fatemi | L. Poisson | C. L. Nemeth | Jaspreet Singh | Bela Turk | Richard O Jones | J. Goodman | J. Singh | C. Nemeth
[1] Lingyi Li,et al. MicroRNA-432-5p inhibits cell migration and invasion by targeting CXCL5 in colorectal cancer , 2021, Experimental and therapeutic medicine.
[2] Fengshou Chen,et al. Altered expression of MiR-186-5p and its target genes after spinal cord ischemia–reperfusion injury in rats , 2019, Neuroscience Letters.
[3] A. Moser,et al. X‐linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies , 2019, International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience.
[4] G. Dhaunsi,et al. Selective receptor-mediated impairment of growth factor activity in neonatal- and X-linked adrenoleukodystrophy patients , 2019, Journal of pediatric endocrinology & metabolism : JPEM.
[5] Nguyen Phuoc Long,et al. Integrative lipidomic and transcriptomic analysis of X-linked adrenoleukodystrophy reveals distinct lipidome signatures between adrenomyeloneuropathy and childhood cerebral adrenoleukodystrophy. , 2019, Biochemical and biophysical research communications.
[6] Qingxiu Zhang,et al. MiR‐409‐3p and MiR‐1896 co‐operatively participate in IL‐17‐induced inflammatory cytokine production in astrocytes and pathogenesis of EAE mice via targeting SOCS3/STAT3 signaling , 2018, Glia.
[7] Jing Su,et al. MiR‐134‐5p attenuates neuropathic pain progression through targeting Twist1 , 2018, Journal of cellular biochemistry.
[8] A. Fatemi,et al. Dendrimer–N‐acetyl‐L‐cysteine modulates monophagocytic response in adrenoleukodystrophy , 2018, Annals of neurology.
[9] A. Moser,et al. Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy , 2017, JAMA neurology.
[10] Sun-Hee Park,et al. Hypoxanthine causes endothelial dysfunction through oxidative stress-induced apoptosis. , 2017, Biochemical and biophysical research communications.
[11] Navjot Shah,et al. MicroRNA Profiling Identifies miR-196a as Differentially Expressed in Childhood Adrenoleukodystrophy and Adult Adrenomyeloneuropathy , 2017, Molecular Neurobiology.
[12] Chao-Ching Huang,et al. CXCL5 signaling is a shared pathway of neuroinflammation and blood–brain barrier injury contributing to white matter injury in the immature brain , 2016, Journal of Neuroinflammation.
[13] A. Moser,et al. Brain endothelial dysfunction in cerebral adrenoleukodystrophy. , 2015, Brain : a journal of neurology.
[14] Y. Gui,et al. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease , 2015, Oncotarget.
[15] F. Villarroya,et al. Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy. , 2015, Human molecular genetics.
[16] S. Giri,et al. MicroRNA Regulation of Proinflammatory Response in X-linked Adrenoleukodystrophy , 2015 .
[17] F. Eichler,et al. The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis. , 2015, The application of clinical genetics.
[18] S. Kapoor,et al. Plasma level of hypoxanthine/xanthine as markers of oxidative stress with different stages of obstructive sleep apnea syndrome , 2014, Annals of Saudi medicine.
[19] P. Svenningsson,et al. 7α-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid reflects the integrity of the blood-brain barrier , 2014, Journal of Lipid Research.
[20] Kira S. Sheinerman,et al. Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies , 2013, Front. Cell. Neurosci..
[21] M. Hiyoshi,et al. A Brain-specific Grb2-associated Regulator of Extracellular Signal-regulated Kinase (Erk)/Mitogen-activated Protein Kinase (MAPK) (GAREM) Subtype, GAREM2, Contributes to Neurite Outgrowth of Neuroblastoma Cells by Regulating Erk Signaling* , 2013, The Journal of Biological Chemistry.
[22] X. Jiang,et al. Regulation of μ‐opioid type 1 receptors by microRNA134 in dorsal root ganglion neurons following peripheral inflammation , 2013, European journal of pain.
[23] F. Kelly,et al. Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy , 2011, Human molecular genetics.
[24] D. Dessem,et al. Downregulation of selective microRNAs in trigeminal ganglion neurons following inflammatory muscle pain , 2007, Molecular pain.
[25] Michael E. Greenberg,et al. A brain-specific microRNA regulates dendritic spine development , 2006, Nature.
[26] Steve Meaney,et al. Crossing the barrier: Published, JLR Papers in Press, March 1, 2005. DOI 10.1194/jlr.M500024-JLR200 net flux of 27-hydroxycholesterol into the human brain , 2005, Journal of Lipid Research.
[27] P. Vreken,et al. Effect of dehydroepiandrosterone supplementation on fatty acid and hormone levels in patients with X‐linked adrenoleucodystrophy , 2003, Clinical endocrinology.
[28] F. Speleman,et al. Modulation of the peroxisomal gene expression pattern by dehydroepiandrosterone and vitamin D: therapeutic implications. , 2002, The Journal of endocrinology.
[29] L. Gooren,et al. Signs of testicular insufficiency in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy: a retrospective study. , 1997, International journal of andrology.
[30] D. Waxman. Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator. , 1996, The Journal of endocrinology.
[31] C. Slaughter,et al. Peroxisome proliferation and induction of peroxisomal enzymes in mouse and rat liver by dehydroepiandrosterone feeding. , 1990, Journal of steroid biochemistry.
[32] R. Simon,et al. Plasma hypoxanthine and exercise. , 1987, The American review of respiratory disease.
[33] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.